HIV :: Boehringer Ingelheim’s patent rights are no obstacle to access to ARV drugs in developing countries
On the occasion of World Aids Day 2006 Boehringer Ingelheim stated that its patent rights to Viramune (nevirapine) do not prevent access to this medication in low income countries.